Porownywarka

Chonluten vs Cortagen side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

ChonlutenCortagen

Udostępnij porównanie peptydów

Wlasciwosc	Chonluten	Cortagen
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Glu-Asp-Gly, EDG	Ala-Glu-Asp-Pro, AEDP
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical research; reported supplement approval in Russia; not FDA or EMA approved Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; source also reports approval in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Respiratory health, lung function, bronchial support	Brain function, cognitive support, neuroprotection
Jak dziala	Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.	Cortagen is presented as part of the Khavinson short-peptide bioregulator model. The source describes a hypothesis in which small peptides can reach the cell nucleus and associate with DNA and histone proteins, potentially influencing gene expression instead of signaling primarily through a membrane receptor. For Cortagen, the proposed tissue focus is the brain cortex and neuronal repair biology. The source cautions that this peptide-DNA concept remains a hypothesis from a limited research lineage and has relatively thin independent validation.
Typowe dawkowanie	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily
Dawkowanie z badań	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typowy czas trwania	10-30 day cycles	10-30 day cycles
Podanie	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.) Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.) Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)	Generally well tolerated (Reported by the source, but detailed safety data are limited.) Limited safety data outside Russia (The source flags this as an evidence limitation.) Not FDA approved (This is a regulatory limitation listed by the source, not a physiological side effect.)
Podsumowanie researchu	The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.	The source highlights a rat sciatic-nerve injury experiment in which intramuscular Cortagen at 10 micrograms per kilogram for 10 days was associated with faster regenerating fiber growth and higher conduction velocity after nerve cutting and suturing. It also cites a Khavinson organ-culture paper reporting selective stimulation of rat brain cortex explants. Other described evidence includes small in vitro or animal studies from the same research environment, including gene-expression and aging-model work. The source does not identify Western randomized controlled human trials for cognition, neuroprotection, or other outcomes, so the overall evidence base remains preliminary.
Referencje	Źródło Źródło +2 więcej Źródło Źródło	PubMed PubMed +3 więcej SpringerLink MDPI Molecules PubMed Central
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Chonluten

Cortagen

Kategoria

Bioregulatory

Znany tez jako

Glu-Asp-Gly, EDG

Ala-Glu-Asp-Pro, AEDP

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical research; reported supplement approval in Russia; not FDA or EMA approved

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; source also reports approval in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Respiratory health, lung function, bronchial support

Brain function, cognitive support, neuroprotection

Jak dziala

Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.

Cortagen is presented as part of the Khavinson short-peptide bioregulator model. The source describes a hypothesis in which small peptides can reach the cell nucleus and associate with DNA and histone proteins, potentially influencing gene expression instead of signaling primarily through a membrane receptor. For Cortagen, the proposed tissue focus is the brain cortex and neuronal repair biology. The source cautions that this peptide-DNA concept remains a hypothesis from a limited research lineage and has relatively thin independent validation.

Typowe dawkowanie

10-20 mg daily · Once or twice daily

Dawkowanie z badań

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typowy czas trwania

10-30 day cycles

Podanie

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.)
Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.)
Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)

Generally well tolerated (Reported by the source, but detailed safety data are limited.)
Limited safety data outside Russia (The source flags this as an evidence limitation.)
Not FDA approved (This is a regulatory limitation listed by the source, not a physiological side effect.)

Podsumowanie researchu

The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.

The source highlights a rat sciatic-nerve injury experiment in which intramuscular Cortagen at 10 micrograms per kilogram for 10 days was associated with faster regenerating fiber growth and higher conduction velocity after nerve cutting and suturing. It also cites a Khavinson organ-culture paper reporting selective stimulation of rat brain cortex explants. Other described evidence includes small in vitro or animal studies from the same research environment, including gene-expression and aging-model work. The source does not identify Western randomized controlled human trials for cognition, neuroprotection, or other outcomes, so the overall evidence base remains preliminary.

Referencje

Źródło Źródło

+2 więcej

Źródło Źródło

PubMed PubMed

+3 więcej

SpringerLink MDPI Molecules PubMed Central

Pełny profil

Zobacz szczegóły